UPDATE: Oppenheimer Downgrades Macrocure Ltd (MCUR) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Macrocure Ltd. Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell(R) in Venous Leg Ulcers
August 19, 2015 6:40 PM EDTPETACH TIKVA, Israel, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure" or the "Company") (NASDAQ: MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell® the Company's lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) determined that this study is not expected to meet its primary endpoint.
"While we are disappointed with the results of the VLU futility analysis, given the positive clinical... More
